Gary A. Bellus

Gary A. Bellus

Auto-generated profile, based on publicly available information

Gary A. Bellus

Medical Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland

Research Focus & Metrics

Academic Career Length

46Years (1981-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 1995 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
GBGary A. Bellus
Gary A. Bellus
IMIain McIntosh
Iain McIntosh
ESE. Anne Smith
E. Anne Smith
AAArthur S. Aylsworth
Arthur S. Aylsworth
IKIlkka Kaitila
Ilkka Kaitila
CFClair A. Francomano
Clair A. Francomano

1 October 1996 in Nature Genetics
Verified
Journal Article
Closed access
GBGary A. Bellus
Gary A. Bellus
KGKarin Gaudenz
Karin Gaudenz
EZElaine H. Zackai
Elaine H. Zackai
LCLorne Clarke
Lorne Clarke
JSJinny Szabo
Jinny Szabo
MMMaximilian Muenke
Maximilian Muenke

1 September 1998 in The American Journal of Human Genetics
Verified
Journal Article
Open access
DWDouglas J. Wilkin
Douglas J. Wilkin
JSJinny K. Szabo
Jinny K. Szabo
RCRhoda Cameron
Rhoda Cameron
SHShirley Henderson
Shirley Henderson
GBGary A. Bellus
Gary A. Bellus
CFClair A. Francomano
Clair A. Francomano
More than 97% of achondroplasia cases are caused by one of two mutations (G1138A and G1138C) in the fibroblast growth factor receptor 3 (FGFR3) gene, which results in a specific amino acid substitution, G380R. Sporadic cases of achondroplasia have been associated with advanced paternal age, suggesting that these mutations occur preferentially during spermatogenesis. We have determined the parental origin of the achondroplasia mutation in 40 sporadic cases. Three distinct 1-bp polymorphisms were identified in the FGFR3 gene, within close proximity to the achondroplasia mutation site. Ninety-nine families, each with a sporadic case of achondroplasia in a child, were analyzed in this study. In this population, the achondroplasia mutation occurred on the paternal chromosome in all 40 cases in which parental origin was unambiguous. This observation is consistent with the clinical observation of advanced paternal age resulting in new cases of achondroplasia and suggests that factors influencing DNA replication or repair during spermatogenesis, but not during oogenesis, may predispose to the occurrence of the G1138 FGFR3 mutations.

14 July 2015 in Human Mutation
Verified
Journal Article
Open access
PDF file
KRKitiwan Rojnueangnit
Kitiwan Rojnueangnit
JXJing Xie
Jing Xie
AGAlicia Gomes
Alicia Gomes
ASAngela Sharp
Angela Sharp
TCTom Callens
Tom Callens
LMLudwine Messiaen
Ludwine Messiaen
Neurofibromatosis type 1 (NF1) is one of the most frequent genetic disorders, affecting 1:3,000 worldwide. Identification of genotype–phenotype correlations is challenging because of the wide range clinical variability, the progressive nature of the disorder, and extreme diversity of the mutational spectrum. We report 136 individuals with a distinct phenotype carrying one of five different NF1 missense mutations affecting p.Arg1809. Patients presented with multiple café‐au‐lait macules (CALM) with or without freckling and Lisch nodules, but no externally visible plexiform neurofibromas or clear cutaneous neurofibromas were found. About 25% of the individuals had Noonan‐like features. Pulmonic stenosis and short stature were significantly more prevalent compared with classic cohorts (P < 0.0001). Developmental delays and/or learning disabilities were reported in over 50% of patients. Melanocytes cultured from a CALM in a segmental NF1‐patient showed two different somatic NF1 mutations, p.Arg1809Cys and a multi‐exon deletion, providing genetic evidence that p.Arg1809Cys is a loss‐of‐function mutation in the melanocytes and causes a pigmentary phenotype. Constitutional missense mutations at p.Arg1809 affect 1.23% of unrelated NF1 probands in the UAB cohort, therefore this specific NF1 genotype–phenotype correlation will affect counseling and management of a significant number of patients.

1 December 2000 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
PDF file
GBGary A. Bellus
Gary A. Bellus
ESElaine B. Spector
Elaine B. Spector
PSPhyllis W. Speiser
Phyllis W. Speiser
CWChristine A. Weaver
Christine A. Weaver
AGAnthony T. Garber
Anthony T. Garber
CFClair A. Francomano
Clair A. Francomano

1 March 1999 in The American Journal of Human Genetics
Verified
Journal Article
Open access
PDF file
PTPatricia L. Tavormina
Patricia L. Tavormina
GBGary A. Bellus
Gary A. Bellus
MWMelanie K. Webster
Melanie K. Webster
MBMichael J. Bamshad
Michael J. Bamshad
AFAlexander E. Fraley
Alexander E. Fraley
CFClair A. Francomano
Clair A. Francomano
We have identified a novel fibroblast growth factor receptor 3 (FGFR3) missense mutation in four unrelated individuals with skeletal dysplasia that approaches the severity observed in thanatophoric dysplasia type I (TD1). However, three of the four individuals developed extensive areas of acanthosis nigricans beginning in early childhood, suffer from severe neurological impairments, and have survived past infancy without prolonged life-support measures. The FGFR3 mutation (A1949T: Lys650Met) occurs at the nucleotide adjacent to the TD type II (TD2) mutation (A1948G: Lys650Glu) and results in a different amino acid substitution at a highly conserved codon in the kinase domain activation loop. Transient transfection studies with FGFR3 mutant constructs show that the Lys650Met mutation causes a dramatic increase in constitutive receptor kinase activity, approximately three times greater than that observed with the Lys650Glu mutation. We refer to the phenotype caused by the Lys650Met mutation as "severe achondroplasia with developmental delay and acanthosis nigricans" (SADDAN) because it differs significantly from the phenotypes of other known FGFR3 mutations.